Table 2 Characteristics of the cohorts of patients with CocaineUD before and after propensity-score matching performed on all listed variables.

From: Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US

 

Before propensity-score matching

After propensity-score matching

CocaineUD

COVID-19 (+) cohort

COVID-19 (−) Cohort

SMD

COVID-19 (+) cohort

COVID-19 (−) Cohort

SMD

Total number

23,687

192,335

 

22,420

22,420

 

Age at index (years, mean ± SD)

46.3 ± 14.3

45.2 ± 14.0

0.08

46.1 ± 14.3

46.2 ± 14.0

0.006

Sex (%)

  Female

41.4

37.8

0.07

41.1

40.9

0.004

  Male

58.6

62.1

0.07

58.9

59.1

0.004

Ethnicity (%)

  Hispanic/Latinx

10.3

8.5

0.06

10.2

10.6

0.01

  Not Hispanic/Latinx

68.2

63.5

0.09

68.1

68.3

0.004

  Unknown

21.5

27.9

0.15a

21.6

21.1

0.01

Race (%)

  Asian

0.7

0.8

0.02

0.6

0.6

0.008

  Black

36.6

36.7

0.002

36.8

37.0

0.004

  White

51.5

50.5

0.02

51.1

51.1

0.001

  Unknown

10.3

11.2

0.03

10.5

10.5

0.001

Adverse socioeconomic determinants of health (%)

32.2

19.5

0.29a

31.7

31.7

0.001

Endocarditis related comorbidities and procedures (%)

  Congenital heart diseases

3.8

1.88

0.12a

3.7

3.6

0.005

  Gingivitis and periodontal diseases

3.8

2.4

0.08

3.6

3.6

0.001

  Dental caries

11.9

8.2

0.12a

11.8

11.5

0.01

  Rheumatic heart diseases

6.2

2.5

0.18a

5.8

5.9

0.001

  Rheumatic fever

0.2

0.1

0.03

0.2

0.2

0.003

  Hemodialysis

1.5

0.4

0.08

1.4

1.6

0.01

  Surgical procedures involving heart and artery

11.4

6.0

0.19a

11.2

11.4

0.005

  Cardiac catheterization

6.0

3.0

0.15a

5.6

5.7

0.005

  Cardiac and vascular implants and grafts

9.0

4.8

0.17a

8.6

8.7

0.002

  Opioid use disorder

31.7

25.6

0.13a

31.6

32.2

0.01

Other potential cardiovascular risk factors

  Obesity and overweight

28.7

15.9

0.31a

27.9

27.6

0.006

  Type 2 diabetes

25.9

15.3

0.26a

25.2

25.2

0.001

  Hypertension

49.8

35.1

0.30a

48.9

48.8

0.003

  Cancer

33.9

20.0

0.32a

32.4

31.6

0.02

Disorders involving the immune mechanisms

4.6

2.2

0.14a

4.3

4.3

0.001

  Atrial fibrillation and flutter

7.5

3.7

0.17a

7.3

7.4

0.006

  HIV

6.6

4.7

0.09

6.3

6.1

0.007

  Viral hepatitis

20.7

15.6

0.13a

20.5

20.3

0.004

  Liver diseases

21.7

12.4

0.25a

20.9

20.8

0.002

  Chronic kidney disease

16.2

7.2

0.28a

15.8

15.9

0.003

  Tobacco use

33.4

20.1

0.31a

32.4

31.9

0.009

Medications

  Chemotherapy

9.1

4.4

0.19a

8.6

8.4

0.008

  Corticosteroids

43.9

24.8

0.41a

43.2

42.8

0.006

  Dexamethasone

30.2

16.0

0.34a

29.2

28.8

0.007

  Immunosuppressants

3.8

1.6

0.13a

3.6

3.5

0.002

  Antidepressants

57.0

39.7

0.35a

56.1

56.2

0.002

  Antipsychotics

39.8

28.2

0.25a

39.5

40.0

0.009

  Anticonvulsants

47.0

31.4

0.32a

46.3

46.2

0.001

  CNS stimulants

18.0

9.2

0.26a

17.6

17.1

0.01

Other CNS medications

38.8

24.8

0.31a

38.0

37.8

0.005

EHR-documented COVID-19 vaccination

4.2

0.1

0.29a

0.4

0.4

0.008

  1. COVID-19 (+) cohort patients with CocaineUD who contracted COVID-19 during 1/2020-4/2022, COVID-19 (−) cohort patients with CocaineUD who had no documented COVID-19 but had medical encounters with healthcare organizations during 1/2020-4/2022, SMD standardized mean differences.
  2. aSMD greater than 0.1, a threshold being recommended for declaring imbalance.